Tectonic Therapeutic Announces Positive Topline Data from Phase 1b Part B Clinical Trial for TX45 in Patients with Group 2 Pulmonary Hypertension in HFrEF

Stock Information for Tectonic Therapeutic Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Tectonic Therapeutic Inc.

Tectonic Therapeutic to Participate in December Investor Conferences
Tectonic Therapeutic Announces Third Quarter 2025 Financial Results and Recent Business Highlights
Tectonic Therapeutic to Participate in September Investor Conferences
Tectonic Therapeutic Announces Second Quarter 2025 Financial Results and Recent Business Highlights
Tectonic Therapeutic Joins Russell 3000® Index
Tectonic Therapeutic Presents Complete Results for Positive Phase 1b Clinical Trial of TX45 in Patients with Group 2 Pulmonary Hypertension in HFpEF in Late-Breaking Presentation at ESC Heart Failure 2025
Tectonic Therapeutic To Present on May 15th, 2025 at the Bank of America Securities Health Care Conference
Tectonic Therapeutic to Present Phase 1b Data for TX45 at European Society of Cardiology Heart Failure 2025

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.